Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Bosentan Therapy for Pulmonary Arterial Hypertension
2.714
Zitationen
12
Autoren
2002
Jahr
Abstract
The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.
Ähnliche Arbeiten
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
2015 · 6.938 Zit.
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
2010 · 6.928 Zit.
Vascular endothelial cells synthesize nitric oxide from L-arginine
1988 · 4.765 Zit.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
2014 · 4.543 Zit.
Updated Clinical Classification of Pulmonary Hypertension
2013 · 4.187 Zit.
Autoren
Institutionen
- University of California, San Diego(US)
- University of Colorado Health(US)
- NewYork–Presbyterian Hospital(US)
- University of Bologna(IT)
- The Royal Free Hospital(GB)
- University College London(GB)
- St Vincent's Hospital Sydney(AU)
- Instituto Nacional de Cardiología(MX)
- Baylor College of Medicine(US)
- Actelion (Switzerland)(CH)
- Harvard University(US)
- Boston Children's Hospital(US)
- Hôpital Antoine-Béclère(FR)